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Abstract
Background: The type 2 iodothyronine deiodinase (D2) converts the pro-hormone thyroxine into T3 within target tissues.
D2 is essential for a full thermogenic response of brown adipose tissue (BAT), and mice with a disrupted Dio2 gene (D2KO)
have an impaired response to cold. BAT is also activated by overfeeding.
Methodology/Principal Findings: After 6-weeks of HFD feeding D2KO mice gained 5.6% more body weight and had 28%
more adipose tissue. Oxygen consumption (V02) was not different between genotypes, but D2KO mice had an increased
respiratory exchange ratio (RER), suggesting preferential use of carbohydrates. Consistent with this, serum free fatty acids
and b-hydroxybutyrate were lower in D2KO mice on a HFD, while hepatic triglycerides were increased and glycogen content
decreased. Neither genotype showed glucose intolerance, but D2KO mice had significantly higher insulin levels during GTT
independent of diet. Accordingly, during ITT testing D2KO mice had a significantly reduced glucose uptake, consistent with
insulin resistance. Gene expression levels in liver, muscle, and brown and white adipose tissue showed no differences that
could account for the increased weight gain in D2KO mice. However, D2KO mice have higher PEPCK mRNA in liver
suggesting increased gluconeogenesis, which could also contribute to their apparent insulin resistance.
Conclusions/Significance: We conclude that the loss of the Dio2 gene has significant metabolic consequences. D2KO mice
gain more weight on a HFD, suggesting a role for D2 in protection from diet-induced obesity. Further, D2KO mice appear to
have a greater reliance on carbohydrates as a fuel source, and limited ability to mobilize and to burn fat. This results in
increased fat storage in adipose tissue, hepatic steatosis, and depletion of liver glycogen in spite of increased
gluconeogenesis. D2KO mice are also less responsive to insulin, independent of diet-induced obesity.
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Introduction
Thyroid hormone regulates a variety of processes including
growth, development, and metabolic rate [1]. The thyroid gland
produces predominantly thyroxine (T4), which has intrinsically
low biological activity. However, this can be increased 10-times by
the enzyme-catalyzed removal of an outer-ring iodine to produce
3,39,5-triiodothyronine (T3) by the type 1 and 2 deiodinases (D1
and D2), an essential step in modulating thyroid hormone action.
The type 3 deiodinase (D3), and under some conditions D1, can
inactivate T3 and T4 by the elimination of an inner-ring iodine,
generating 3,39-T2 or reverse 3, 39,5 9 T3 (rT3) respectively. Thus,
the iodothyronine deiodinases modulate T3 action by regulating
its production and degradation at both a systemic and tissue-
specific level [2].
The D2 enzyme plays a key role in the local production of T3
from T4 within specific tissues. Over 30 years ago D2 activity was
originally described when the mechanism of suppression of TSH
in the pituitary by T4 was elucidated [3]. These findings were
further confirmed in mice with a targeted deletion of the type 2
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found to be decreased by treatment with T3, but not T4 [4]. The
importance of D2-mediated local generation of T3 from T4 has
also been established in many other diverse processes including
chondrocyte differentiation, cochlear development, optimal bone
strength and mineralization, and muscle regeneration after
wounding [5–8].
Perhaps one of the best characterized functions of D2 is its
essential role in mediating a full thermogenic response of brown
adipose tissue (BAT) to adrenergic stimulation via increased T4 to
T3 conversion within this tissue [9–11]. Further elegant studies in
D2KO mice have shown that these animals are deficient in both
lipolysis and lipogenesis leading to BAT dysfunction, and only
survive cold exposure by a compensatory increase in shivering
[12,13].
BAT is considered a tissue with a dual function, being activated
during cold exposure and also during overfeeding [[14] and
references therein]. Given the importance of D2 in normal BAT
recruitment, it is surprising that D2KO mice do not have a
phenotype reflecting a significant disruption of energy balance.
Both increased and decreased weight gain have been associated
with models of BAT dysfunction. For example, mice with a
targeted ablation of BAT due to a tissue-specific transgenic
expression of diphtheria toxin from the uncoupling protein 1
(UCP1) gene promoter are obese, although it is possible that the
obesity of this mouse model is caused by hyperphagia rather than
reduced thermogenesis [15]. Additional mouse models with
impaired BAT function such as mice with a deletion of all 3 b-
adrenergic receptors, and knock in of a dominant negative
mutation in TRa (P398H), have increased weight gain even on a
chow diet [16,17]. On the other hand, other models of BAT
dysfunction have a paradoxical resistance to obesity such as mice
with targeted deletion of the UCP-1 gene, or deletion of all
isoforms of TRa (Thra-0/0), or a knock in of a different dominant
negative mutation in TRa (R384C) [18–20]. In these models it is
thought that BAT impairment leads to alternative, more
energetically costly forms of facultative thermogenesis, resulting
in a resistance to obesity. In support of this, the reduced sensitivity
to obesity in these mouse models is attenuated as ambient
temperature is increased, and disappears at thermoneutrality
where there is no need to defend core temperature [18–20].
In this work we report studies where the weight gain of D2KO
mice on a high fat diet (HFD) was compared to congenic wild type
controls, and we find that there is a modest, but significant,
increase in weight gain in D2KO mice. In addition, our data
indicates that D2KO mice are insulin resistant on a chow diet,
even without increased weight gain. We conclude that the loss of
the Dio2 gene results in significant metabolic consequences.
Methods
Animal Treatment Protocols
Animals were maintained and experiments were performed
according to protocols approved by the Animal Care and Use
Committee of Harvard Medical School and Baystate Medical
Center. D2KO mice were generated as previously described [4] in
collaboration with Drs. Donald St. Germain and Valerie Galton.
The D2KO mice used in this study were backcrossed for 11-
generations with C57BL/6 mice from Jackson Labs (Bar Harbor,
ME) and can be considered congenic with C57BL/6 mice except
for the targeted disruption of the Dio2 gene [21]. Control animals
were also derived from C57BL/6 mice from Jackson Labs, and
were bred, born, and raised in our animal facility in parallel with
D2KO mice. For energy expenditure experiments control mice
were purchased from Jackson Labs, and were maintained in
parallel in the same animal facility 2 weeks before use. Under these
conditions D2KO showed a similar increase in weight gain when
on a HFD (data not shown). Mice were maintained for 6 weeks on
either a control diet of standard chow (# 7001) or 21% milk fat
diet (48% of calories derived from fat) (# 95121) from Harlan
Teklad as described [22]. Mice were 9-weeks old at the start of the
diet, with average starting weights being 22.860.3 g and
22.560.3 g for wild type and D2KO mice on a HFD, while
starting weights were 21.860.6 g and 22.860.3 g for wild type
and D2KO mice on a chow diet.
Glucose and Insulin Tolerance Testing
Glucose and insulin tolerance testing were performed as
described previously [23–25]. Briefly, for glucose tolerance testing
mice were fasted 14 h, and injected intra-peritoneally with 2 g/kg
D-glucose. 0 to 120 minutes after injection, glucose levels were
measured using a glucometer (One Touch Ultra, Lifescan) in
blood collected from the tail vein. Blood was also collected at 0, 30
and 120 minutes from the same mice for measurement of insulin
levels. For insulin tolerance testing, mice were fasted 14 h, then
injected with intra-peritoneally with 0.5 mU/g body weight. Blood
glucose levels were then measured from 0 to 120 minutes after
injection, as in glucose tolerance testing. The HOMA-IR index
was calculated as described [26].
Deiodinase Activity
D2 assays were performed as described [27,28]. Muscle D2 was
measured by assaying 75–100 mg of microsomal protein, while
BAT D2 activity was measured by assaying 50 mg of homogenate
for 3 hours at either 1 nM (specific) or 100 nM T4 (non-specific
background).
qRT-PCR
Quantitative Real-Time PCR (qRT PCR) was performed as
described previously [29] with the following modifications:
SuperScript VILO (Invitrogen, Carlsbad CA) was used for cDNA
synthesis following the manufacturer’s instructions. Sequences of
primers used are listed in Table S1. All samples were normalized
for the amount input of mRNA using Cyclophilin A expression, a
commonly used housekeeper that we have found to be
independent of thyroid status [28].
Serum Hormone/Chemistry Measurements
Levels of total serum T3 and T4 were measured as described
previously [29]. Serum triglyceride and glycerol levels were
determined using a serum triglyceride measurement kit from
Sigma, while b-hydroxybutyrate and free fatty acid levels were
measured using colorimetric assays at the Joslin Diabetes Center
Specialized Assay Core. Serum insulin levels were measured using
an Insulin EIA kit (ALPCO).
Liver Triglyceride Content
Liver triglycerides were extracted by incubating 100 mg of
minced liver with 15 ml of 1:2 methanol: chloroform and 3 ml of
0.05% H2SO4 overnight at room temperature. 1 ml of the lower
phase was transferred to a new tube and 0.5 ml chloroform +1%
triton X-100 added, and samples were dried using nitrogen.
Samples were then resuspended in 1–3 ml water as needed and
triglycerides were measured using a triglyceride quantification kit
(Abcam, Cambridge MA) following the manufacturer’s instruc-
tions for fluorometric assay.
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Glycogen content was determined via acid hydrolysis followed
by measurement of glucose [30,31]. In brief, ,10 mg of liver was
homogenized in 0.5 ml 2 N HCl, boiled for 2 hours, and
neutralized with an equal volume of 2 N NaOH. Samples for
background glucose determination were homogenized in 0.5 ml
0.03 N HCL, boiled for 5 minutes, and neutralized by an equal
volume of 0.03 N NaOH. Glucose content was measured using
glucose (hexokinase) assay reagent from Sigma (St. Louis, MO).
Measurement of Body Composition by MicroCT
Body Composition was measured at the Longwood Small
Animal Imaging Facility of Beth Israel Deaconess Medical Center.
Mice were anesthetized with 2% isoflurane/balance O2. Imaging
was performed using the CT component of a NanoSPECT/CT
(Bioscan, Washington, DC) scanner equipped with an 8 W X-ray
source running at 45 kVp (177 mA) and a 48 mm pitch CMOS-
CCD X-ray detector. Continuous helical micro-CT scanning was
employed with the following parameters: 1 s exposure, 240 angles,
1.3 magnification, 37 mm pitch (1 field-of-view), and a 5126256
pixel frame size (192 mm pixels). Images were reconstructed as
1706170 pixel transverse matrices with varying axial length and
slice thickness of 0.1 mm (isotropic voxel size 0.1 mm) using
filtered-back projection (Shepp-Logan filtering). Quantitation of
body fat was performed using InVivoScope software (Bioscan,
Inc.)
Measurement of V02 and RER
Energy expenditure was measured as described previously by
indirect calorimetry using an open-circuit system (Qubits System,
Kingston, Ontario Canada) [19]. Measurements were done over a
24-hour period, and begun at mid-afternoon after mice had
several hours to adjust to the chambers. Mice had ad libitum access
to food and water during the course of experiments, and there was
no significant change in the weight of mice under these conditions.
Statistical Analysis
Prism 4.0 software (GraphPad Software, San Diego CA) was
used for statistical analysis. When only two groups were analyzed,
statistical significance was determined using an unpaired Student’s
t-test. Two-way ANOVA was used to compare the effects of
different diets (chow and HFD) on two genotypes (WT and
D2KO), and when significant differences were observed individual
means of columns were compared by unpaired Student’s t-test as
indicated. Repeated measure based parameters (such as weight
gain over time or GTT) were analyzed using two-way ANOVA for
repeated measures followed by Bonferroni correction. Statistical
details (p-value, F, and degree of freedom (Df)) are provided in the
figure legends along with the results of the two-way ANOVA
testing. p,0.05 was considered statistically significant.
Results
D2KO mice gain more weight on a high fat diet
We first compared weight gain of D2KO mice backcrossed 11-
generations in a C57BL/6 background with control C57BL/6
mice on a chow and high fat diet containing 21% milk fat (HFD)
for 6-weeks (Fig. 1A). While male wild type and D2KO mice both
gained similar amounts of weight on a chow diet, notably, D2KO
mice gained 5.6% more weight than control animals (p,0.001)
(Fig. 1A,B). Analysis of the percentage of body fat using micro CT
confirmed no difference between genotypes on chow; however,
D2KO mice had 28% more body fat than wild type animals when
on a HFD (p,0.05) (Fig. 1C,D). Despite their increased weight
gain, D2KO mice did not eat more than control animals, with WT
and D2KO mice having the same caloric intake on either diet
(Fig. 1E). Similar results were found when female mice were
studied with D2KO female mice gaining more weight on HFD
than WT mice and having with 43% more body fat after 6 weeks
of HFD (p,0.001) (Fig. S1).
On a chow diet no difference in oxygen consumption (VO2)o r
respiratory exchange ratio (RER) was observed between genotypes
(data not shown). On a HFD, VO2 was not different between
genotypes, but RER was greater in the D2KO genotype (p,0.05),
indicatingthattherelativecontributionofcarbohydratetooxidative
metabolism is increased (Fig. 2 A, B, C, D). Notably, during
darkness (indicated by the bar), when rodents eat, the difference
between the average RER is even more marked, being 0.8260.003
versus0.8060.004(p,0.001).Applying the Luskequation [32],this
means that D2KO were burning 39% of carbohydrate and 61% of
fat, whereas the WT burned 31% carbohydrate and 69% fat
(p,0.001) during this period, despite both being on the same diet.
D2KO mice are insulin resistant even on a chow diet
Since increased body fat is associated with insulin resistance, we
assessed if the greater weight gain of D2KO mice would lead to
differences in glucose handling and insulin responsiveness. Fasting
blood glucoselevels weresignificantlyhigherinD2KO mice on chow
(p,0.01), while corresponding insulin levels showed a tendency to be
higher (Table 1). Accordingly, the HOMA index was also higher in
D2KO mice (p,0.05). When glucose tolerance testing was
performed on male chow-fed D2KO and control mice glucose
clearance was not different between genotypes, however insulinlevels
in the D2KO group were 2.5-times that of wild type animals 120
minutes after glucose injection (p,0.05) (Fig. 3A,B,C,D). When the
HFD groups were studied, D2KO mice had significantly higher
fasting glucose and insulin levels (p,0.01 and p,0.05) with an
increase in their HOMA index (p,0.01) (Table 2). With GTT,
overall the glucose clearance between D2KO and wild type animals
appeared similar (Fig. 3E,F). Notably, after glucose injection the
increase in insulin levels in D2KO mice was much greater, being
double that of controls at 120 minutes (p,0.01) (Fig. 3G,H). Results
of glucose tolerance testing in HFD fed female D2KO mice were
similar to those of males, with no difference in glucose levels over a
time course of 120 minutes (Fig. S2A,B) while insulin levels were
significantly higher at both 30 and 120 minutes (Fig. S2C,D).
The above results indicate that D2KO mice require greater
amounts ofinsulinto normalize their serum glucose levels suggestive
of insulinresistance, and thus we performed insulin tolerance testing
to confirm this. Glucose levels were significantly higher in D2KO
mice on a chow diet at 90 minutes after a single i.p. injection of
insulin (p,0.05),with theintegratedareaunderthe curve alsobeing
significantly greater in D2KO mice (p,0.05) (Fig. 4A,B). D2KO
mice on a HFD have significantly higher blood glucose levels after
insulin injection with values being significantly increased at 90 and
120minutes(p,0.001and 0.01),withthe integratedareaunderthe
curve also indicating that D2KO mice have a decreased response to
insulin (p,0.01) (Fig. 4C,D). Furthermore, D2KO mice on a HFD
showed a paradoxical rise in blood glucose levels that was
particularly evident at late times after insulin injection. Taken
together these results indicate that the D2KO mice have abnormal
glycemic control, and peripheral resistance to the action of insulin.
Remarkably, these defects are apparent when mice are on a chow
diet, even before increased weight gain.
Assessment of serum and liver biochemistry
To define the metabolic consequences of HFD feeding in
D2KO mice, we first determined levels of relevant serum markers.
Insulin Resistant D2KO with Increased Weight Gain
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wild type and D2KO animals, while T4 had a tendency to be
increased in D2KO mice on a standard chow diet [4,27]
(Fig 5A,B). Diet had a positive effect on both serum T3 and T4
independent of genotype, with both being increased after 6 weeks
of HFD to similar extents in both wild type and D2KO mice
(p,0.001 and p,0.05 by two-way ANOVA) (Fig 5A,B). Triglyc-
eride levels were not significantly different between genotypes and
did not change with diet, although they had a tendency to be
elevated in D2KO mice on a chow diet (Fig. 5C). FFA levels were
lower in D2KO mice on a HFD when compared to the control
animals (p,0.05) (Fig. 5D), while b-OH-butyrate was increased in
D2KO mice on chow when compared to controls (p,0.01)
(Fig. 5E).
In the liver, triglyceride content was increased by 57% in
D2KO mice on a HFD (p,0.01) (Fig. 5F). Strikingly, glycogen
content was significantly decreased by greater than 60–80% in
D2KO mice on both chow and a HFD (p,0.001 and p,0.05)
(Fig. 5G). Overall, the above results are consistent with a
preferential use of carbohydrates/impairment of fatty acid
utilization in D2KO mice on a HFD.
Gene expression patterns in liver, muscle, and brown and
white adipose tissue of wild type and D2KO mice on
chow and a HFD
Expression levels of genes relevant to glucose and fatty acid
metabolism were measured in brown and white adipose tissue,
liver, and muscle of wild type and D2KO mice on both diets
(Fig 6A–F). While numerous genes changed in both genotypes in
response to HFD feeding, no obvious differences were observed
that could explain the increased weight gain of D2KO mice on a
HFD. In BAT no significant changes in mRNA levels were found,
beside the reduction of acetyl CoA carboxylase 1 (ACC1)
expression when mice were on a HFD independent of genotype
(p,0.5 by two-way ANOVA) (Fig. 6A). However, in wild type
mice, D2 gene expression showed a tendency to be increased by
HFD feeding in this tissue (Fig. 6A), correlating with a 2.9-fold
Figure 1. Male D2KO mice weight gain and body fat on a HFD. (A) Body weight of wild type and D2KO mice on chow or a HFD for 6-weeks,
n=22–24 mice/genotype for HFD group, n=5 mice/genotype for chow group. A significant interaction between genotype and diet were determined
by two-way ANOVA for repeated measures (p,0.001; F=33.55; Df=312). After Bonferroni correction, there was a significant difference in weight gain
of D2KO vs. WT after 4, 5 and 6 weeks of diet (p,0.05, 0.01 and 0.001). (B) Weight gain expressed as % of initial weight after 6 weeks on either chow
or a HFD of mice shown in (A). Two-way ANOVA indicated a significant interaction between genotype and diet (2WA g6d) (p,0.05; F=7.11; Df=52).
(C) % body fat as determined by microCT, n=4–5 mice/group. Two-way ANOVA indicated a significant interaction between genotype and diet
(p,0.05; F=4.87; Df=15). (D) Density of voxels falling in the Hounsfield Unit range defined for adipose tissue of a representative wild type and D2KO
mouse. Red is more dense while purple is less in the colorbar range. (E) Average food intake of wild type and D2KO mice on either a chow or HFD was
monitored for 7 days at 3 weeks of diet and is shown expressed as kcal/day/mouse. Two-way ANOVA indicated that diet significantly effected the
overall caloric consumption independent of genotype (2WA d) (p,0.01; F=10.25; Df=16). When a significant interaction between genotype and diet
was found individual means were compared within groups by unpaired Student’s t-test. Data presented are the mean 6 SEM; *=p,0.05,
**=p,0.01, ***=p,0.001, ns=not significant.
doi:10.1371/journal.pone.0020832.g001
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tissue, ACC1 was also significantly decreased by HFD feeding
independent of genotype (p,0.5 by two-way ANOVA) (Fig. 6B).
In liver, peroxisome proliferator activated receptor a (PPARa),
carnitine palmitoyltransferase 1 a (CPT1a), and a-gylcerolpho-
sphate dehydrogenase (aGPD) were all increased when mice were
on a HFD, independent of the genotype (p,0.05, p,0.01, and
p,0.001 by two-way ANOVA) (Fig. 6C). Levels of PEPCK, a
marker of gluconeogenesis, increased when mice were fed a HFD
(p,0.001 by two-way ANOVA), and further were increased to a
greater extent in D2KO mice (p,0.01 by two-way ANOVA),
consistent with the increased serum glucose levels found in D2KO
mice (Fig. 6C, Table 1, Table 2). Previously we have found low D2
mRNA expression and activity in liver of mice and rats that can be
modulated by diet, however no D2 mRNA or activity were
detectable in these experiments [22,33].
In soleus there were no striking changes in gene expression
between either genotype on chow or HFD, although the
expression of malonyl CoA decarboxylase (MCD) was significantly
increased by HFD feeding for both genotypes (Fig. 6D) (p,0.05 by
two-way ANOVA). D2 mRNA was increased 2.5-fold by a HFD
in the soleus of wild type mice (p,0.05) (Fig. 6D), although D2
activity remained unchanged (data not shown). In vastus lateralis
muscle genotype significantly effected the expression of glycogen
synthetase 1 (GSY1) and hexokinase (HK), with levels of these
genes being greater in D2KO mice independent of diet (Fig. 6E)
(p,0.05 by two-way ANOVA). Glucose transporter 4 (GLUT4)
was also increased in chow-fed D2KO mice (p,0.05), while this
Figure 2. VO2 consumption and RER of wild type and D2KO mice on a HFD. (A) 24-hour VO2 profile of wild type and D2KO mice on a HFD.
Each point represents the mean of 5 mice measured every 35 minutes. The black bar below the X-axis represents the dark period during which mice
would be feeding. (B) Histograms representative of the areas under the curve of (A). (C) 24-hour RER of wild type and D2KO mice on a HFD. Each
point represents the mean of 5 mice measured every 35 minutes. (D) Histograms representative of the areas under the curve of (C) Data presented
are the mean 6 SEM; *=p,0.05, ns=not significant.
doi:10.1371/journal.pone.0020832.g002
Table 1. Fasting glucose and insulin levels of WT and D2KO
mice on chow diet.
WT D2KO
n 10 10 P value
fasting glucose (mg/dL) 82.162.2 95.663.5 ,0.01
fasting insulin (ng/mL) 0.3560.04 0.4860.06 ns
HOMA index 1.7560.21 2.8560.38 ,0.05
Mean 6 SEM is shown. Male WT and D2KO mice were 9 week old at time of
testing. HOMA index was calculated as fasting glucose (mg/dl) x fasting
insulin(mU/mL)/405 as in [26].
doi:10.1371/journal.pone.0020832.t001
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a HFD.
Discussion
In these studies we report that D2KO mice gained 5.6% more
weight than wild type mice when challenged for 6-weeks with a
HFD (Fig. 1A,B). Although this represents a modest percentage
increase, body fat of D2KO mice was increased by 28% when
compared to wild type mice (Fig. 1C,D). Notably, previous studies
have shown that even a small amount of weight loss and decrease
in adiposity can significantly decrease the risk of developing
diabetes and cardiovascular disease [34–37].
Surprisingly, the increased weight gain of D2KO mice is not the
result of increased food intake, or decreased energy expenditure
since VO2 consumption was the same between both genotypes
when mice had ad libitum access to food. Interestingly, in a
subsequent set of experiments, during fasting D2KO showed a
significant reduction in VO2 consumption as compared to wild
type controls, suggesting that D2KO mice do have reduced energy
expenditure under some conditions [38]. RER measurement
indicates that D2KO mice burn ,8% more carbohydrate, and
correspondingly less fat, despite their apparent insulin resistance
(Fig. 2–4, Table 1, Table 2). Additionally, serum levels of free fatty
acids and b-hydroxybutyrate were lower in D2KO mice on a
HFD, indicating that fatty acid mobilization/oxidation might be
impaired. Consistent with these findings, hepatic triglycerides were
increased in D2KO mice fed a HFD, while glycogen levels are
lower despite increased PECK suggestive of increased gluconeo-
genesis (Fig. 5D–G, Fig. 6C). Taken together, our results suggest
that on a HFD D2KO mice may have an increased reliance on
carbohydrate as a fuel source with a tendency to accumulate the
fat that is not utilized, and that this in turn could be one of the
factors contributing to the increased weight gain of D2KO mice
on a HFD. Pyruvate kinase dehydrogenases (PDKs) are key
regulators of glucose oxidation via phosphorylation of the pyruvate
dehydrogenase complex, and mice with a targeted deletion of
PDK 4 exhibit a preferential usage of glucose in muscle [39,40].
Figure 3. Glucose tolerance testing and corresponding insulin levels of wild type and D2KO mice on a chow and HFD. (A) Wild type
and D2KO mice maintained on a chow diet were fasted for 14 h, and then injected IP with 2 g/kg D-glucose at time 0 indicated by the arrow. Blood
glucose levels were measured at the indicated time, and are not significantly different by two-way ANOVA for repeated measures. (B) Histograms
representative of the areas under the curve of (A). (C) Corresponding serum insulin levels of mice in (A). A significant difference was found by two-
way ANOVA for repeated measures after Bonferroni correction at 1209 (p,0.05). D) Histograms representative of the areas under the curve of (C). (E)
Same as (A) except mice were maintained for 6-weeks on a HFD prior to testing, values are not significantly different by two-way ANOVA for repeated
measures. (F) Histograms representative of the area under the curve of (E). (G) Corresponding serum insulin levels of mice in (E). A significant
interaction was found by two-way ANOVA for repeated measures (p,0.05; F=4.26, Df=16). A significant difference was found after Bonferroni
correction at 1209 (p,0.01). (H) Histograms representative of the area under the curve of (G). N=5–6 mice/group, male mice were 15 weeks old time
of at testing. Data shown are the mean 6 SEM with *=p,0.05, **=p,0.01, ns=not significant.
doi:10.1371/journal.pone.0020832.g003
Table 2. Fasting glucose and insulin levels of WT and D2KO
mice on high fat diet (HFD).
WT D2KO
n 16 16 P value
fasting glucose (mg/dL) 102.066.0 130.867.6 ,0.01
fasting insulin (ng/mL) 0.2860.05 0.5360.1 ,0.05
HOMA index 1.8660.33 4.1060.72 ,0.01
Mean 6 SEM is shown. Male WT and D2KO mice were 15–16 weeks old and on
HFD for 6 weeks, at the time of testing. HOMA index was calculated as fasting
glucose (mg/dl) x fasting insulin(mU/mL)/405 as in [26].
doi:10.1371/journal.pone.0020832.t002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20832Both PDK 2 and 4 are T3-responsive genes, and expression of
some, but not all, T3-responsive genes has been found to be
impaired in D2KO mice [8,13,41–43]. However, PDK2 and 4 are
mRNA levels are unchanged in D2KO mice, and the molecular
basis of preferential carbohydrate usage in D2KO mice remains to
be defined (Fig. 6D,E).
D2 activity has been described in BAT, white adipose tissue,
muscle, liver and brain [22,33,44–47]. Due to the global loss of D2
in our model, the absence of D2 in any of these tissues could
contribute to the increased weight gain of the D2KO mice.
However, D2 activity was unmeasurable in liver and white adipose
tissue of our wild type mice in these experiments, thus any effects
observed in these tissues are most likely indirect.
The hypothalamus is a D2 containing tissue that plays a key role
in energy homeostasis (reviewed in [2,48]). Hypothalamic D2 has
been shown to be important in UCP-2 mediated re-feeding
behavior, and D2KO mice consume less food immediately after
fasting [49]. However our results indicate that under conditions of
ad libitum feeding alterations in food intake did not contribute to
the increased weight gain found in D2KO mice (Fig. 1 E). AMPK
in the hypothalamus is also T3-regulated, with central adminis-
tration of T3 in rats decreasing AMPK activity [50]. This in turn
leads to increased sympathetic nervous system activity and BAT
stimulation, resulting in an up-regulation of thermogenic markers
and weight loss. With this in mind, a loss of D2 might result in
impaired local generation of T3 from T4 in the ventromedial
nucleus of the hypothalamus in D2KO mice, resulting in
decreased tissue-T3 content. This could lead to increased AMPK
activity and decreased sympathetic nervous system activity,
resulting in impaired activation of brown adipose tissue (BAT)
favoring increased weight gain. Furthermore, decreased sympa-
thetic stimulation of the liver might also lead to increased hepatic
triglyceride accumulation. However, in this regard, D2KO mice
have increased norepinephrine turnover in BAT, indicating
increased sympathetic activity, suggesting that the mechanism
detailed above is not the explanation for their increased weight
gain [13,51]. Additionally, while the increased hepatic triglyceride
levels found in D2KO mice could be a result of decreased
sympathetic stimulation of the liver, on the other hand, their
increased levels of PEPCK, suggesting increased gluconeogenesis,
and decreased glycogen content, are consistent with increased
sympathetic stimulation (Fig. 5 F,G, Fig. 6C) [52–54]. Thus, there
are likely to be multiple factors contributing to the hepatic
phenotype of the D2KO mice.
D2 activity is increased by 2.9-fold in the BAT of wild type mice
with HFD feeding, consistent with the increased activation of this
tissue found during diet induced thermogenesis. Given the key role
BAT plays in energy expenditure, it seems likely that BAT dysfunction
could be contributing to the increased weight gain found in D2KO.
Indeed, many mouse models show an inverse relationship between D2
in BAT and adiposity [18,19,55]. Fu r t h e r ,a ni n c r e a s ei nD 2i nB A T
(andpotentially othertissues)isnecessary forbile acidsupplementation
to increase energy expenditure in mice fed a HFD, thus conferring
resistance to diet induced obesity to these animals [56]. However, it
should be noted, that whatever the mechanism behind the increased
weight gain of D2KO mice, it is not simply the result of impaired BAT
function leading to decreased oxygen consumption (Fig. 2). In this
regard, increased D2 expression in liver, muscle, and WAT has also
been described in other models of resistance to weight gain, although
the significance of this has yet to be fully understood [18,19,22,57].
While our data suggests that a loss of D2 in liver and WAT may not be
relevant in our model, a loss of D2 in skeletal muscle could result in
significant consequences, given the major role played by this tissue in
glucose disposal and fuel consumption [58].
Figure 4. Insulin tolerance testing of wild type and D2KO mice on chow and HFD. (A) wild type and D2KO mice maintained on a chow diet
were fasted for 14 h, and then injected IP with 0.5 mU/g body weight insulin at time 0 indicated by the arrow. A significant difference was found by
two-way ANOVA for repeated measures after Bonferroni correction at 909 (p,0.05). (B) Histograms representative of the area under the curve of (A).
(C) Same as (A) except mice were maintained for 6-weeks on a HFD prior to testing. Two-way ANOVA for repeated measures showed a significant
interaction (p,0.05; F=3.09; Df=55). Significant differences were found after Bonferroni correction at 909 and 1209 (p,0.001 and p,0.01) (D)
Histograms representative of the area under the curve of (C). N=5–7 mice/group, male mice were 15 weeks old time of at testing, data shown are the
mean 6 SEM with *=p,0.05, **=p,0.01, ***=p,0.001.
doi:10.1371/journal.pone.0020832.g004
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have increased resistance to insulin when on a HFD as denoted by
greaterinsulinlevelsduringGGT,a decreasedglucose uptakeduring
ITT, and an increased HOMA index, as might be expected due to
their increased adiposity (Fig. 3, 4, Table 2). However, it is
remarkable that even at 9-weeks of age when on a chow diet,
D2KO mice have higher fasting glucose levels and an increased
HOMA index (Table 1), and also have greater insulin levels during
GGT and a decreased glucose uptake during ITT (Fig. 3, 4), all
consistent with insulin resistance of D2KO even prior to increased
weight gain. This phenotype is in agreement with other work
showing that primary cultures of both brown adipocytes and
myocytes lacking D2 have reduced levels of Akt phosphorylation
after insulin stimulation [43,59]. Additionally, increased triglyceride
accumulation in liver, as found in the D2KO mice, has been
correlated with insulin resistance (Fig. 5F)[60]. Gene expression
profiles further indicate that D2KO mice have higher levels of
PEPCK in liver, and this difference is magnified with high fat diet
feeding, suggesting that increased gluconeogenesis could play a role
in the increased fasting glucose levels found in the D2KO mice
(Fig. 6C). With this in mind, we cannot rule out that the higher
insulin levels found in D2KO mice may in part be due to
compensation for increased gluconeogenesis. Nonetheless, D2KO
mice exhibit alterations in glucose homeostasis that are consistent
with a pre-diabetic state [61].
In humans, D2 has been linked to insulin resistance, with a
polymorphism in the human Dio2 coding region (Thr92Ala)
found at a frequency of 0.32 in the general population, and 0.75
Figure 5. Serum and liver biochemistry of wild type and D2KO mice on chow and HFD. Levels of T3 (A) T4 (B), (C) triglycerides, (D) free
fatty acids, or (E) b-hydroxybutyrate in serum are shown. Hepatic levels of (F) triglycerides or (G) glycogen are also indicated. Data are analyzed by
two-way ANOVA. There was a significant effect of diet (2WA d) on T3 (p,0.001; F=16.45; Df=19) and T4 (p,0.05; F=4.73; Df=20) independent of
genotype. Two-way ANOVA indicated a significant interaction between diet and genotype (2WA g6d) for serum FFA (p,0.001; F=4.91; Df=20); b-
hydroxybutyrate (p,0.01; F=8.55; Df=19), hepatic triglycerides (p,0.05; F=6.31; Df=19) and hepatic glycogen (p,0.05; F=5.37; Df=20). When a
significant interaction between genotype and diet was found individual means were compared within groups by unpaired Student’s t-test and
showed in the figure. Data shown are the mean 6 SEM of 4–5 mice/group on chow diet or 7–10 mice/group on HFD with *=p,0.05, **=p,0.01,
***=p,0.001, ns=not significant.
doi:10.1371/journal.pone.0020832.g005
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studies [62–66]. In line with this, hypothyroidism has also been
associated with insulin resistance that can be improved with
thyroid hormone treatment [67]. Our work indicating that
D2KO mice are insulin resistant even before increased weight
gain would further support a role for D2 in the modulation of
insulin sensitivity.
While this paper was under review, other studies were published
by Castillo et al. detailing the effects of HFD feeding on D2KO
mice [51]. In contrast to our results, this work did not find
increased weight gain in D2KO mice fed a HFD at room
temperature, while D2KO weight gain with HFD feeding was
increased when mice were maintained at thermoneutrality to
minimize the effects of increased sympathetic tone. We speculate
that the closer match between the starting weights of our mice
(22.8 g wild type and 22.5 g D2KO versus ,26 g wild type and
,21 g D2KO) and a greater number of animals in our study (22–
24/genotype versus 4–5/genotype) may have allowed us to
uncover what otherwise might have been a subtle phenotype.
Castillo et al. also report that chow-fed D2KO mice have
increased glucose clearance during GTT that is lost with HFD
feeding, with no data on the corresponding insulin levels in these
mice [51]. However, our results are more consistent with other
work from the same group that found that no difference in glucose
clearance during GTT between chow-fed wild type and D2KO
mice [68]. Lastly, both our groups find no change in VO2 in HFD
fed D2KO mice at room temperature, and an elevation of hepatic
triglyceride content [51].
In summary, our results indicate that a loss of the Dio2 gene in
mice results in greater weight gain, hepatic steatosis on a HFD,
and insulin resistance even before D2KO mice have increased
adipose tissue. Further, D2 may play an important role in
regulating intermediary metabolism and fuel partition. Taken
together as a whole, our data suggests that D2 could be an
important target in terms of modulation of adiposity, and in the
regulation of insulin action.
Figure 6. Levels of gene expression in wild type and D2KO mice on chow and HFD. mRNA levels of the indicated genes were measured
using qRT PCR, and then corrected by Cyclophillin A expression as a house-keeping gene. Data is normalized to expression of wild type mice on a
chow diet, and expression levels in (A) BAT, (B) WAT, (C) liver, (D) soleus, and (E) vastus lateralis are shown. Significant effects were determined by
two-way ANOVA. A significant interaction between genotype and diet (2WA g6d) was found in vastus lateralis for GLUT4 (p,0.01; F=8.79; Df=16). A
significant effect of diet (2WA d) independent of genotype was found in BAT for ACC1 In BAT (p,0.05; F=6.02; Df=16), in WAT for ACC1 (p,0.05;
F=5.41; Df=16), in liver for PPARa(p,0.05; F=6.0; Df=16), PEPCK (p,0.001; F=30.19; Df=16), aGPD (p,0.01; F=12.21; Df=16), CPT1a (p,0.001;
F=21.87; Df=16), and in soleus for MCD (p,0.01; F=6.95; Df=8). A significant effect of genotype (2WA g) independent of diet was found in liver for
PEPCK (p,0.01; F=8.91; Df=16) and in vastus lateralis for GYS1 (p,0.05; F=8.02; Df=16) and HK (p,0.01; F=5.9; Df=16). When a significant
interaction between genotype and diet was found individual means were compared within groups by unpaired Student’s t-test. N=5 mice/group
except for soleus were n=3–4 with each sample being solei pooled from 3 mice. Data shown are the mean 6 SEM; *=p,0.05, **=p,0.01,
***=p,0.001, ns= not significant.
doi:10.1371/journal.pone.0020832.g006
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Figure S1 Female D2KO mice weight gain and body fat
on a HFD. (A) Body weight of wild type and D2KO mice on
chow or a HFD for 6-weeks. n=4–5 mice/group. A significant
interaction between genotype and diet was determined by two-way
ANOVA for repeated measures (p,0.001; F=21.02; Df=96).
After Bonferroni correction, there was a significant difference in
weight gain of D2KO vs. WT starting at week 2 (B) Weight gain
expressed at % of initial weight after 6 weeks on either chow or a
HFD of mice shown in (A), two-way ANOVA indicated a
significant interaction between genotype and diet (2WA g6d)
(p,0.05; F=7.52; Df=16). (C) Weight of dissected perigonadal,
mesenteric, perirenal, subcutaneous and brown adipose tissue fat
depots divided by total body weight was used to calculate adiposity
index as in [18], two-way ANOVA indicated a significant
interaction between genotype and diet (2WA g6d) (p,0.0001;
F=37.52; Df=16). (D) Average food intake of wild type and
D2KO mice on either a chow or HFD was monitored for 7 days at
3 weeks of diet and is shown expressed as kcal/day/mouse. Two-
way ANOVA indicated diet significantly effected the overall
caloric consumption independent of genotype (2WA d) (p,0.001;
F=15.41; Df=16). Data shown are the mean 6 SEM,
*=p,0.05, **=p,0.01, ***=p,0.001, ns=not significant.
(TIF)
Figure S2 Glucose tolerance testing and corresponding
insulin levels of female wild type and D2KO mice on a
HFD. Female wild type and D2KO mice were maintained for 6-
weeks on a HFD prior to testing. (A) Results of glucose tolerance
testing performed as in Fig. 3A are shown. Blood glucose levels
were measured at the indicated time, and are not significantly
different by two-way ANOVA for repeated measures. (B)
Histograms representative of the area under the curve of (A). (C)
Corresponding serum insulin levels of mice in (A) Two-way
ANOVA for repeated measures showed a significant effect (p
value,0.01; F=8.15, Df=16). After Bonferroni correction
significant differences were found at 909 and 1209 (p,0.05 and
p,0.001) (D) Histograms representative of the area under the
curve of (C). N=4–5 mice/group, female mice were 15 weeks old
time of at testing. Data shown are the mean 6 SEM with
*=p,0.05, **=p,0.01; ns=not significant.
(TIF)
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